News
Yuhan Corporation Receives $15 Million Milestone from Janssen for Launch of Lazertinib + Amivantamab Combination Therapy in Japan
Yuhan Corporation announced that it will receive a milestone payment of $15 million (approximately 20.7 billion KRW) from Janssen Biotech, a subsidiary of the multinational
Yuhan Presents Preclinical Data on Targeted Therapy YH42946 and Bispecific Immunotherapy YH32364
At the AACR 2025 Annual Meeting, Yuhan Corporation unveiled promising preclinical results for two of its cancer drug candidates: YH42946, a HER2/EGFR tyrosine kinase inhibitor
Yuhan’s HER2×4-1BB Bispecific Antibody YH32367 Shows Early Efficacy and Safety in Phase 1 Solid Tumor Trial
At the AACR 2025 Annual Meeting, Yuhan Corporation presented encouraging interim results from a Phase 1 trial of YH32367, a bispecific antibody targeting HER2 and
Lazertinib + Amivantamab Combo from J&J Posts Strong Q1 Sales, Strengthening Its Position in NSCLC Treatment
Johnson & Johnson (J&J) reported that the combination therapy of Lazertinib (brand name Leclaza in Korea) and Amivantamab (brand name Rybrevant) achieved impressive global sales
RYBREVANT® plus LAZCLUZE™ shows statistically significant and clinically meaningful improvement in overall survival versus osimertinib
J&J는 EGFRxMET 이중항체 ‘아미반타맙 (제품명 리브리반트)’와 유한양행이 개발해 J&J에 라이선스아웃한 3세대 EGFR TKI ‘레이저티닙 (제품명 라즈클루즈)’가 타크리소 대비 환자의 OS를 통계적으로, 임상적으로 유의미하게 개선했다고 밝힘.